Leishmaniasis is a neglected tropical disease affecting millions of people worldwide. A centenary approach to antimonial-based drugs was first initiated with the synthesis of urea stibamine by Upendranath Brahmachari in 1922. The need for new drug development led to resistance toward antimoniates. New drug development to treat leishmaniasis is urgently needed. In this way, searching for new substances with antileishmanial activity, we synthesized ten anthranyl phenylhydrazide and three quinazolinone derivatives and evaluated them against promastigotes and the intracellular amastigotes of Leishmania amazonensis. Three compounds showed good activity against promastigotes 1b, 1d, and 1g, with IC50 between 1 and 5 μM. These new phenylhydrazides were tested against Leishmania arginase, but they all failed to inhibit this parasite enzyme, as we have shown in a previous study. To explain the possible mechanism of action, we proposed the enzyme PTR1 as a new target for these compounds based on in silico analysis. In conclusion, the new anthranyl hydrazide derivatives can be a promising scaffold for developing new substances against the protozoa parasite.
Leishmaniasis is a significant public health concern, affecting millions and causing substantial mortality, thus urgently requiring more effective and safer treatments. This study explored the potential of 33 novel N-acylhydrazone-derived compounds against Leishmania amazonensis parasites, focusing on their inhibition of the Leishmania arginase enzyme and promastigote growth. Compounds 8 and 18 showed over 90% inhibitory activity against promastigote cultures after 72 h of treatment. Compound 8 showed an IC50 of 10.5 µM (9.4–11.8 µM), while compound 18 exhibited an IC50 of 42.8 µM (41.3–44.4 µM). The antipromastigote effects of these compounds highlight their potential for further new drug design. These findings offer a promising starting point for addressing the pressing need for new therapeutic options against leishmaniasis. In addition, we used web-based tools to predict the compounds’ toxicity and pharmacokinetic parameters. Despite the lack of inhibition against the L. amazonensis arginase enzyme, further investigation into the mechanisms of action of these compounds and in vivo efficacy could contribute to the development of safer and more effective treatments for this neglected tropical disease.
5 September 2022 in Research, Society and Development
O objetivo do estudo foi avaliar a evolução da produção e exportação de ovos de poedeiras comerciais no Brasil, considerada para o período de 2007 a 2021. Foram utilizados procedimentos metodológicos que incluíram além da pesquisa bibliográfica e documental, coleta e análise de informações obtidas junto aos órgãos governamentais e imprensa responsável pelo setor. Em 2020, o Brasil foi o 5º maior produtor mundial de ovos comerciais. Em 2021, a região sudeste foi responsável pela maior produção de ovos no país. Em 2021, o consumo de ovos do brasileiro foi de 257 per capita e está abaixo quando comparado a outros países, como o México, com um consumo de 368 ovos em 2020 e os Estados Unidos da América, com um consumo de 289 ovos em 2019. Entre os anos de 2007 e 2021 houve um aumento expressivo do consumo per capita de ovos pelos brasileiros, de 49,03%. Em 2021, as exportações brasileiras para ovos in natura (69,7%) e industrializados (30,3%) obtiveram resultado inexpressivo, representando 0,46% do total produzido, mas há expectativas de melhorias para os próximos anos, com abertura de novos mercados. O Brasil demonstrou crescimento contínuo tanto na produção, quanto no consumo per capita de ovos. Há necessidade de investimento em novas tecnologias, bem como adequação às normas de sanidade e segurança alimentar, e ainda, que as agências responsáveis pela divulgação dos valores nutricionais do ovo junto à população brasileira se tornem mais eficazes e atuem no mercado de ovos industrializados, principalmente no mercado de exportação.
Web applications are widespread and can be accessed from anywhere, in theory, using aweb browser on a computer or smartphone. Primarily due to the diversity of web browsers and frameworks available for developing web application interfaces, testing such applications is a challenging task. With the advent of large language models, several works are utilizing them to automate software engineering tasks, including test case generation. This use of LLMs for test case generation prioritizes unit testing. More recently, we have seen the advent of Generic Artificial Intelligence Agents, which are tools that utilize LLMs and also possess the ability to run additional tools, such as cloning repositories, navigating websites, and compiling programs. In this work, which is part of a research and development project, we evaluate a specific Generic AI Agent Assistant regarding its capability to navigate web applications and create fully automated end-to-end test cases, utilizing Selenium WebDriver and JUnit 5 framework. Results show that, considering a set of nine websites, in overall end-to-end test case generation, Suna configured with DeepSeek V3 produced 165 successful test cases out of 481 generated tests, a success rate of 34.3%. On the other hand, Suna configured with Claude Sonnet 4 produced 336 successful test cases out of 479 generated tests, a success rate of 70.1%, which is very impressive, mainly due to the complexity of creating end-to-end testing. In terms of cost, we used a free and a paid LLM model. The paid model generates successful test cases at an average price of $ 0.15 per test case.